We therefore can propose that GABP might be a potential biomarker in glioma classification, but further investigations must be made in order to elucidate the actual relationship between TERT and GABPA/B isoforms in gliomas, aiming for targeted therapy in the future. This evidence concerns the gene TERT and central nervous system cancer.